GENE SIGNATURE OF RESIDUAL RISK FOLLOWING ENDOCRINE TREATMENT IN EARLY BREAST CANCER

• Main Authors: YAO CINDY Q, BAYANI JANE, BARTLETT JOHN MS, BOUTROS PAUL C
• Format: Patent
• Language: Chinese; English
• Published: 21.12.2018
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMBINATORIAL CHEMISTRY; COMPOSITIONS OR TEST PAPERS THEREFOR; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES; ENZYMOLOGY; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES; LIBRARIES, e.g. CHEMICAL LIBRARIES, IN SILICOLIBRARIES; MEASURING; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS; METALLURGY; MICROBIOLOGY; MUTATION OR GENETIC ENGINEERING; PHYSICS; PROCESSES OF PREPARING SUCH COMPOSITIONS; SPIRITS; TESTING; VINEGAR; WINE

There is described herein a method of prognosing endocrine-only treatment in a subject with breast cancer, the method comprising: a) providing a tumor sample of the breast cancer; b) determining the expression level of at least 40 of the genes listed in Table 4 in the tumor sample; c) comparing said expression levels to a reference expression level of the group of genes from control samples from acohort of subjects; and d) determining the residual risk associated with the breast cancer; wherein a statistically significant difference or similarity in the expression of the group of genes compared to the reference expression level corresponds to a residual risk associated with breast cancer. 本文描述了在乳腺癌受试者中预后仅内分泌治疗的方法，所述方法包括：a)提供乳腺癌肿瘤样品；b)确定所述肿瘤样品中表4所列基因中至少40个的表达水平；c)将所述表达水平与来自受试者群组的对照样品的基因组群的参考表达水平相比；和d)确定与乳腺癌有关的剩余风险；其中，与参考表达水平相比，所述基因组群表达中的统计学显著差异或相似性对应于与乳腺癌有关的剩余风险。